TY - JOUR T1 - Parkinson’s disease: evolution of cognitive impairment and CSF Aβ<sub>1–42</sub> profiles in a prospective longitudinal study JF - Journal of Neurology, Neurosurgery &amp; Psychiatry JO - J Neurol Neurosurg Psychiatry SP - 165 LP - 170 DO - 10.1136/jnnp-2018-318956 VL - 90 IS - 2 AU - Stefanie Lerche AU - Isabel Wurster AU - Benjamin Röben AU - Gerrit Machetanz AU - Milan Zimmermann AU - Felix Bernhard AU - Elke Stransky AU - Christian Deuschle AU - Claudia Schulte AU - Oskar Hansson AU - Henrik Zetterberg AU - Thomas Gasser AU - Daniela Berg AU - Walter Maetzler AU - Kathrin Brockmann Y1 - 2019/02/01 UR - http://jnnp.bmj.com/content/90/2/165.abstract N2 - Objective To evaluate the evolution of cognitive impairment in relation to cerebrospinal fluid (CSF) profiles of amyloid-β (Aβ), total-Tau and phosphorylated-Tau in Parkinson’s disease (PD).Methods Prospective, longitudinal, observational study up to 10 years with follow-up every 2  years. We assessed CSF profiles in 415 patients with sporadic PD (median age 66; 63% men) and 142 healthy controls (median age 62; 43% men).Results Patients with PD with low CSF Aβ1–42 levels at baseline were more often cognitively impaired than patients with intermediate and high Aβ1–42 levels. Sixty-seven per cent of the patients with low Aβ1–42 levels at baseline and normal cognition developed cognitive impairment during follow-up, compared with 41% and 37% of patients having intermediate and high CSF Aβ1–42 levels. Kaplan-Meier survival curves and Cox regression revealed that patients with low CSF Aβ1–42 levels at baseline developed cognitive impairment more frequently and earlier during follow-up.Conclusion We conclude that in patients with sporadic PD, low levels of Aβ1–42 are associated with a higher risk of developing cognitive impairment earlier in the disease process at least in a subgroup of patients. ER -